You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Studies on VEGF antibodies.

From: Radiotherapy and "new" drugs-new side effects?

Substance Author(s) Year Study type N tumour RT dose/ChTx/technique Toxicity
Bevacizumab Vredenburgh et al. [147] 2010   125 Glioblastoma 59,4 Gy/Temozolomide Grade III Thromboembolic events: 2%
  Crane et al. [63] 2009 Phase II 82 Pancreatic Cancer 50,4 Gy/Capecitabine Toxicities possibly attributable to bevacizumab: GI bleeding: 6%. (d83,127,179, 180, 316); grade III, IV, V GI perforation: 4%. (d195,231,286) DVT grade III + IV: 4%; grade III hypertension: 2%;
  Lai et al. [72] 2010 Phase II 70 Glioblastoma 60 Gy/Temozolomide Grade IV cerebrovascular ischemia: 9%; Grade III+IV CNS hemorrhage: 3%; Grade III+IV GI bleeding/perforation 6%; grade IIII Optic neuropathy: 1%. Grade III+IV venous Thrombosis/PE: 19%.
  Crane et al. [62] 2006 Phase I 48 Pancreatic Cancer 50,4 Gy/Capecitabine Toxicities possibly attributable to bevacizumab: grade III+V ulceration with bleeding in RT field: 8%. (retrospectively fistulous connection identified in 4%) Grade III GI perforation: 4%; bleeding outside field): 4%; grade III hypertension: 2%.
  Seiwert et al. [148] 2008 Phase I 43 Head & Neck 63-72 Gy/5-FU and Hydroxyurea Grade V bleeding events: 5%; grade V infection/sepsis: 7%, 2% unknown cause of death; grade III+ Thromboembolic events: 5% DVT, 2% stroke (leading to fatal sepsis, see above); fistula (due to radionecrosis or residual tumour): 12%. Tissue necrosis 9%.
  Spigel et al. [149] 2009 Phase II A 29 B 5 SCLC 61,2 Gy/Carboplatin/Irinotecan (A-limited stage B-locally advanced) A Grade IV+V tracheoesophageal fistula: 7%. Grade V aerodigestive hemorrhage. B Grade III tracheoesophageal fistula: 40%. Both studies closed due to toxicity.
  Willet et al. [58] 2009 Phase II 32 Rectal Cancer 50,4 Gy//5-FU Grade III toxicities: GI abscess 3%, Hypertension 9%, radiation dermatitis: 6%; wound separation 3%. No grade IV.
  Dipetrillo et al. [55] 2012 Phase I 26 Rectal Cancer 50,4 Gy/FOLFOX Grade III + IV Diarrhea: 42%; Bleeding (g3): 4%; g3 neuropathy: 4%; Radiation dermatitis G3: 8%; postoperative wound complications: 35%-the study was discontinued due to this toxicity.
  Crane et al. [53] 2010 Phase II 25 Rectal Cancer 50,4 Gy/Capecitabine grade III perianal desquamation: 4%; 12% major surgical complications such as anastomotic dehiscence (4%), wound dehiscence (8%)
  Gutin et al. [68] 2009 Phase I 25 Glioblastoma/Anaplastic Gliomas 30 Gy/5 × 6 Gy Grade IV Gastrointestinal bleeding: 4%, bowel perforation: 4%, wound healing complication: 4%. Grade III CNS hemorrhage: 4%.
  Koukourakis et al. [59] 2009 Phase I/II 22 Rectal Cancer 15 × 3,4 Gy/amifostine, capecitabine Fistula: 9%, grade IV skin necrosis 5%.
  Niyazi et al. [69] 2010 Retrospective 20 Recurrent Glioblastoma 36 Gy Grade IV wound healing complication: 5%. grade III DVT: 5%.
  Koukourakis et al. [150] 2011 Phase II 19 Rectal cancer 10 × 3, 4 Gy Amifostine/Capecitabine Grade III diarrhea: 11%.
  Goyal et al. [65] 2010 Retrospective 14 Breast cancer 50 Gy + 10 Gy No Grade III/IV toxicity (only acute toxicity assessed)
  Czito et al. [61] 2007 Phase I 11 Rectal Cancer 50,4 Gy/Oxaliplatin + Capecitabine No grade III + toxicities attributable to bevacizumab: grade III-IV diarrhea: 27%,
  Resch et al. [151] 2011 Phase II 8 Rectal cancer 45 Gy/Capecitabine Discontinued due to tox after 8 Pt., Grade III GI bleeding: 25%, Grade III diarrhea: 25%
  Kelly et al. [71] 2010 Case reports 3 Glioblastoma   Optic neuropathy
  Vargo et al. [152] 2011 Case report 1 Glioblastoma   Dural venous thrombosis
  1. N-number of patients